Although, to date, no clinical trials have evaluated RAD51 foci formation as a biomarker for therapy response, several retrospective studies have reported that patients with HRD tumors (defined by a RAD51 functional test) show higher platinum sensitivity and improved survival rates [31,35]. Here, RAD51 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.